Protocols

Based on published literature, mecasermin (recombinant human IGF-1) dosing protocols vary significantly depending on the indication and patient population studied.

Primary IGF-1 Deficiency (Approved Indication)

The most established protocols are for severe primary IGF-1 deficiency, where mecasermin is FDA-approved:

Starting dose: Typically 0.04-0.08 mg/kg administered subcutaneously twice daily
Dose escalation: Gradual increases based on tolerance and response, up to maximum of 0.12 mg/kg twice daily
Administration: Given shortly before or after meals to minimize hypoglycemia risk
Monitoring: Regular assessment for hypoglycemia, especially during dose initiation and escalation

Investigational Uses

Limited data exists for other conditions studied in clinical trials:

Rett Syndrome: Phase 2 studies have examined various dosing regimens, though specific protocols from the available evidence are not detailed enough to report precise dosing ranges.

Cardiac Applications: Phase 1/2 trials have investigated IGF-1 in post-myocardial infarction patients, but dosing protocols are not clearly established in the available literature.

Premature Infants: Studies examining bronchopulmonary dysplasia prevention have used investigational formulations, but standard protocols are not yet established.

Safety Considerations

Available evidence emphasizes several important monitoring requirements:

Hypoglycemia monitoring: This appears to be the most significant adverse effect requiring regular blood glucose monitoring
Growth parameter tracking: Regular measurement of growth velocity and bone age
Injection site assessment: Monitoring for lipohypertrophy at injection sites

Evidence Limitations

The available literature provides limited specific dosing details for many investigational uses. Most detailed protocols are available only for the approved indication of severe primary IGF-1 deficiency. For other conditions, protocols remain investigational and are not standardized.

Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Mecasermin dosing and administration should only be determined by qualified healthcare providers based on individual patient assessment, approved prescribing information, and current clinical guidelines.

IGF-1 (Mecasermin)

Member access required